Welcome to InfiCure Bio

InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.

Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.

News

LSX Nordic Congress

InfiCure Bio will be presenting at the LSX Nordic Congress in Stockholm on August 28th. The company will be presenting during the start up showcase as one of the growth stage private companies.

Additional funding

InfiCure Bio has received additional funding from NLC InfiCure Bio and Partnerinvest Övre Norrland to speed up the validation of additional indications in the NIF mouse. This is a golden opportunity to broaden our customer [...]

  • Chairman InfiCure Bio

Lena Söderström – new Chairman of the Board

InfiCure Bio is pleased to announce that Lena Söderström has been appointed new Chairman of the Board. Lena has longstanding experience from numerous positions in the life science sector and her knowledge, together with her [...]

EASL in Vienna

InfiCure Bio will be present at this years EASL in Vienna. Julia will present the NIF mouse and Dan will talk about imaging in livers of NIF mice. If you're at EASL, do not hesitate [...]